Decitabine plus filgrastim to prevent relapse after transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Genetic & congenital clinical trials.
This trial tests whether giving decitabine with filgrastim soon after a stem cell transplant can be done safely and may help prevent the leukemia or related cancer from coming back. It is aimed at children and young adults with AML, MDS, or related myeloid cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between ages 1 and 39
- You have a confirmed diagnosis of AML, MDS, myeloid sarcoma, treatment-related myeloid disease, or a related leukemia type
- You are having an allogeneic stem cell transplant (donor transplant) and will join the study before the transplant
- After transplant, you must be in MRD-negative remission (no detectable leftover cancer cells by a specialized blood/bone marrow test)
- Your heart and other organs must be healthy enough for transplant treatment (per hospital standards)
- You can attend clinic visits for at least 7 months and can sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
This study tests whether giving two drugs, decitabine and venetoclax, after a stem cell transplant can help keep your leukemia or MDS from coming back. It is for people whose disease is at high risk for relapse.
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
This trial tests adding two new drugs, decitabine and venetoclax, to a standard reduced-intensity stem cell transplant for people with certain types of leukemia or myelodysplastic syndrome. The goal is to see if this combination can improve outcomes.
This trial tests a new combination of two drugs—leflunomide and decitabine—for people with MDS that has come back or hasn't responded to treatment. The goal is to see if this combination can help control the disease.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.